相关临床试验
289
25 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1789
进行中（未招募）
19
6.6%
Approved For Marketing
1
0.3%
已完成
142
49.1%
Enrolling By Invitation
2
0.7%
尚未招募
4
1.4%
招募中
38
13.2%
终止
47
16.3%
Unknown
22
7.6%
撤回
14
4.8%
暂无批准数据
- An international task force co-led by Georgetown and University of Maryland experts published consensus recommendations for studying molecular biomarkers in stroke recovery on August 19, 2026, in the International Journal of Stroke. - The framework prioritizes understanding recovery as a biological process rather than a single 90-day outcome, aiming to identify the right treatment for the right patient at the right time. - Candidate biomarkers highlighted include neurofilament light chain (NfL), BDNF, brain-derived tau, GFAP, and interleukin-6, with calls for harmonized longitudinal blood sampling and larger international studies. - The task force stresses that biomarker information must never be used to deny patients access to rehabilitation care.
- Genomic testing uptake among Medicare beneficiaries with cancer nearly tripled from 6% in 2016 to 16.7% in 2023, yet overall utilization remains low. - NGS testing adoption was highest in lung cancer patients, while breast cancer patients continued to rely more on non-NGS genomic tests. - Significant disparities in testing rates were observed by age, race, ethnicity, and geography, suggesting insurance coverage alone is insufficient. - Researchers call for further study into barriers to NGS adoption and whether increased testing translates to improved patient outcomes.
- The Cure Innovation Index survey of 117 senior US leaders finds the US leads in technology transfer, capital, commercialization, and talent, while China leads in clinical development and supply chain. - The two countries are viewed as tied in scientific discovery, but 85% of respondents believe the US lead will last 10 years or less. - By 2024, China's share of early drug development programs rose to over 32% from 8% in 2015, while the US share dropped to around 37% from 48%. - Respondents rated growing US research funding cuts as a bigger concern than competition from China, with calls to modernize clinical development infrastructure.
- Georgetown University has launched the Health Security Intelligence Operations Center (HSOC) as an early warning system ahead of the FIFA World Cup, with nearly two dozen analysts tracking global health threats. - The HSOC monitors wastewater sites, electronic records, and international health alerts, producing daily reports for public health officials and FIFA decision-makers covering threats from influenza to Ebola. - With 6.5 million fans expected across North America and weakened federal public health infrastructure, local health departments are independently ramping up disease surveillance, including wastewater and mosquito testing. - Cities are preparing for heat-related injuries, food safety challenges, and infectious disease spread including measles, sexually transmitted infections, and mosquito-borne illnesses like dengue and Zika.
- Despite an ongoing Ebola outbreak in Congo and Uganda designated a public health emergency, experts say the risk of Ebola transmission during the World Cup is extremely low due to its non-respiratory spread. - Measles is the primary concern for public health officials, given its extreme contagiousness, rising U.S. cases (over 2,100 in 2025), and declining vaccination rates. - Host cities are scaling up wastewater surveillance, mobile testing labs, and cross-jurisdictional coordination through new initiatives like Georgetown's Health Security Operations Center. - Respiratory viruses such as Covid-19 and influenza, as well as norovirus and foodborne illnesses, also pose notable risks during the multi-city, three-country tournament.
- New post hoc analysis of the Phase 2 eNRGy trial demonstrates zenocutuzumab-zbco achieved a 35% overall response rate in treatment-naïve NRG1+ NSCLC patients compared to 31% in previously treated patients. - Treatment-naïve patients experienced significantly longer median duration of response at 17.1 months versus 7.4 months in previously treated patients, with all treatment-related adverse events being grade 1 or 2. - The clinical benefit rate reached 65% in treatment-naïve patients compared to 58% in previously treated patients, supporting early intervention with targeted therapy for this rare molecular subset. - Results were presented at the IASLC-ASCO North America Conference on Lung Cancer, reinforcing zenocutuzumab's potential as a first-line treatment option for NRG1-positive NSCLC patients.
- CytoDyn has dosed the first patient in a Phase II clinical trial evaluating leronlimab, a CCR5 antagonist, in patients with relapsed/refractory microsatellite stable colorectal cancer. - The study is being conducted across eight clinical sites in partnership with Syneos Health, with Dr. Ben Weinberg from Georgetown University serving as lead principal investigator. - The trial builds on prior research showing potential clinical benefit of leronlimab in relapsed colorectal cancer and promising survival rates in metastatic triple-negative breast cancer. - Colorectal cancer represents a significant global health burden with approximately 1.9 million new cases and over 900,000 deaths annually worldwide according to WHO data.
- Georgetown University and MedStar Health researchers developed a blood test that uses circulating cell-free DNA fragments to detect early signs of liver transplant rejection and complications. - The technology analyzes DNA methylation patterns to identify the specific cellular origin of organ damage, enabling more targeted treatment approaches. - This liquid biopsy approach could replace invasive liver biopsies and provide continuous monitoring of transplant recipients with greater accuracy. - The research, funded by a $2.5 million NIH grant, represents a major advancement in post-transplant care and has potential applications in other organ transplants and cancer treatment.
- TG01 cancer vaccine demonstrated excellent safety profile and induced mutant RAS-specific T-cell responses in 50% of multiple myeloma patients in a phase 1/2 trial. - Six of twelve patients showed vaccine-induced immune responses, with five maintaining stable disease, suggesting clinical benefit in this difficult-to-treat population. - The study targets RAS-mutant multiple myeloma, which affects 15-20% of patients and has poor prognosis with no available targeted treatments. - Biomarker findings provide mechanistic validation and suggest specific patient selection criteria for future clinical development of the vaccine.
- A randomized controlled trial of 136 Latina breast cancer survivor-caregiver pairs demonstrated high engagement rates, with 71.4% attending at least five of eight intervention sessions and 82% retention at six months. - The culturally tailored group intervention showed clinically meaningful improvements in anxiety and fatigue among survivors at six months compared to usual care controls. - While improvements were clinically significant, statistical significance was not maintained after adjusting for confounding variables, highlighting the complexity of measuring efficacy in community-based interventions. - The study, conducted across Washington D.C., New York City, and San Jose, demonstrates the feasibility of implementing culturally competent psychosocial interventions in underserved populations.
